Leica BOND Ready To Use Primary Antibodies Immunohistochemistry (IHC -Hematologic Disorder and blood cancer marker)
Singapore·CLASS B IVD·Leica Biosystems Newcastle Ltd·Registered February 03, 2021- Device Class
- CLASS B IVD
- Medical Speciality Area
- Immunology
- Registration Number
- DE0505429
- Registration Date
- February 03, 2021
- Change Notification Approval Date
- April 25, 2025
- Retention Due Date
- February 02, 2026
- Short Name
- Leica Biosystems Newcastle Ltd
- Address
- Balliol Business Pk/Benton La, Newcastle upon Tyne NE12 8EW, UNITED KINGDOM
- Address
- 15 TUKANG INNOVATION DRIVE, SINGAPORE 618299
- Address
- 18 BOON LAY WAY, TRADEHUB 21, #05-105, SINGAPORE 609966 15 TUKANG INNOVATION DRIVE, SINGAPORE 618299
- Model Name(s)
- Immunoglobulin D DRN1C CD31 JC70A CD4 (4B12) CD79a (JCB117) Carcinoembryonic Antigen (CD66e) COL-1
- Model Identifier(s)
- PA0061 PA0414 PA0427 PA0599 PA0848
Access comprehensive regulatory information for Leica BOND Ready To Use Primary Antibodies Immunohistochemistry (IHC -Hematologic Disorder and blood cancer marker) in the Singapore medical device market through Pure Global AI's free database. This CLASS B IVD medical device is registered under HSA registration number DE0505429 and owned by Leica Biosystems Newcastle Ltd. The device was registered on February 03, 2021.
This page provides complete registration details including product owner information, registrant details, importer information, and regulatory compliance data from the official Singapore HSA medical device database. Pure Global AI offers free access to Singapore's complete medical device registry, helping global MedTech companies navigate HSA regulations efficiently.